Medgend Icon

Ledgend of Medicine







discontinued


Afinitor FDA Approved Drugs

AFINITOR [EverolimusC53H83NO14]
RX
-
10mg (oral tablet)
2.5mg (oral tablet)
7.5mg (oral tablet)
NovartisMar 30, 2009
  • Treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.
  • Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic.
  • Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected..
  • Treatment of solid excretory system tumors; advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib.
efficacy
2.0  (2)
side effects
0.0  (0)
danger
0.0  (0)

UNK

AFINITOR DISPERZ [EverolimusC53H83NO14]
RX
-
2mg (oral tablet, for suspension)
3mg (oral tablet, for suspension)
5mg (oral tablet, for suspension)
Novartis PharmAug 29, 2012
  • Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected..
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ZORTRESS [EverolimusC53H83NO14]
RX
-
0.25mg (oral tablet)
0.5mg (oral tablet)
0.75mg (oral tablet)
NovartisApr 20, 2010
  • Prophylaxis of allograft rejection in adult patients receiving a liver transplant.
  • Prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a renal transplant.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.